EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Probing 5‐Nitroimidazole‐Triazole Hybrids as Potential Anti‐Kinetoplastid Agents: Synthesis and In Vitro Efficacy

Liandi Ferreira iD, Gideon D Badenhorst, Janine Aucamp iD, Keisuke Suganuma iD, David D N'Da iD

ChemMedChem · 2026-07-14 · 21 (13)

DOI: 10.1002/cmdc.70375 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-07-14. Written by Liandi Ferreira and 4 co-authors. Institution: Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, Potchefstroom, South Africa. Major MEDLINE topics: Triazoles, Nitroimidazoles, Antiprotozoal Agents, Trypanocidal Agents. 55 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Research Foundation, Japan Society for the Promotion of Science, KAKENHI.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Neglected tropical diseases caused by kinetoplastid parasites, including leishmaniasis, human African trypanosomiasis and Chagas disease, remain severely underserved by current chemotherapies, which are limited by toxicity, resistance and poor efficacy. Nitroheterocycles continue to be clinically relevant due to their redox activation within parasites, and the 1,2,3‐triazole linker offers a modular approach by enabling systematic variation of substituents, thereby allowing controlled modulation of physicochemical and biological properties. Accordingly, this study investigated a new library of 5‐nitroimidazole‐1,2,3‐triazole hybrids and evaluated substituent‐dependent effects on their antiparasitic activity. A series of 5‐nitroimidazole‐1,2,3‐triazole hybrids was synthesised via copper(I)‐catalysed azide–alkyne cycloaddition and evaluated in vitro for their antileishmanial and antitrypanosomal activity, alongside cytotoxicity profiling. Most compounds exhibited low toxicity against mammalian cell lines. No antileishmanial hit was uncovered. In the trypanosome panel, 3j demonstrated selective micromolar inhibition against Trypanosoma congolense (IC 50 = 6.38 ± 1.03 µM, SI = 48); hence, it was identified as a trypanocidal hit.

Subjects

MeSH terms (MEDLINE)

TriazolesNitroimidazolesAntiprotozoal AgentsTrypanocidal AgentsHumansStructure-Activity RelationshipParasitic Sensitivity TestsMolecular StructureDose-Response Relationship, DrugAnimalsTrypanosoma cruziCell Survival

Author keywords

hybridsimidazoleleishmaniasisstriazoletrypanosomiasis

Substances

TriazolesNitroimidazolesAntiprotozoal AgentsTrypanocidal Agents

Authors and institutions

  • Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
  • National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan.

ORCID profiles: Liandi Ferreira, Janine Aucamp, Keisuke Suganuma, David D N'Da

Funding

  • National Research Foundation
  • Japan Society for the Promotion of Science
  • KAKENHI

Cite

APA

Ferreira, L., Badenhorst, G. D., Aucamp, J., Suganuma, K., & N'Da, D. D. (2026). Probing 5‐Nitroimidazole‐Triazole Hybrids as Potential Anti‐Kinetoplastid Agents: Synthesis and In Vitro Efficacy. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70375

Vancouver

Ferreira L, Badenhorst GD, Aucamp J, Suganuma K, N'Da DD. Probing 5‐Nitroimidazole‐Triazole Hybrids as Potential Anti‐Kinetoplastid Agents: Synthesis and In Vitro Efficacy. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70375

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Liandi and Badenhorst, Gideon D and Aucamp, Janine and Suganuma, Keisuke and N'Da, David D},
  title = {Probing 5‐Nitroimidazole‐Triazole Hybrids as Potential Anti‐Kinetoplastid Agents: Synthesis and In Vitro Efficacy},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70375}
}
Start for free →